Sanofi Secures EU Approval for Teizeild, Demonstrating Significant Efficacy in Type 1 Diabetes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: NASDAQ.COM
- New Drug Approval: Sanofi's Teizeild receives EU approval as the first disease-modifying therapy for Stage 2 Type 1 Diabetes, demonstrating a median delay of 48.4 months to Stage 3 T1D, significantly enhancing patient quality of life and strengthening the company's competitive position in diabetes treatment.
- FDA Approval: Fortress Biotech's ZYCUBO gains FDA approval as the first treatment for Menkes Disease, showing nearly an 80% reduction in mortality risk when used early, laying a solid foundation for future market expansion and revenue growth.
- Acquisition Deal: Boston Scientific's $14.5 billion acquisition of Penumbra reflects its strategic expansion in interventional therapies, expected to enhance its leadership in vascular treatments and drive future revenue growth.
- Clinical Trial Progress: Creative Medical's CELZ-201 shows significant improvement in 79% of patients in the ADAPT trial for chronic lower back pain, indicating the therapy's clinical potential and likely attracting further investment and partnership opportunities.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BSX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BSX is 125.74 USD with a low forecast of 112.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 93.790
Low
112.00
Averages
125.74
High
140.00
Current: 93.790
Low
112.00
Averages
125.74
High
140.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
This Successful Fund Manager Favors J&J, Lowe’s, and Utility Stocks
- Active Equity Managers: Few active equity managers consistently outperform the S&P 500 index.
- Long-Term Consistency: It is even rarer for these managers to achieve consistent success over many years.
Continue Reading
Boston Scientific Faces Setback; Acquisition of Penumbra Expected to Boost Stock Performance.
- Acquisition Focus: Boston Scientific is heavily focused on acquisitions as part of its growth strategy.
- Stock Impact: The latest acquisition has negatively affected the company's stock in the short term, but it is expected to yield positive results in the future.
- Investor Patience: Investors are encouraged to remain patient as the long-term benefits of the acquisition are anticipated to materialize.
- Future Outlook: Despite current stock challenges, the outlook for Boston Scientific remains optimistic due to its strategic acquisitions.
Continue Reading